The biotech company based in the Sionlla Biopole has signed an agreement with the Chinese firm Chime Biologics to accelerate the development of SRB5, an innovative therapeutic antibody against Crohn’s disease or ulcerative colitis.
Santiago de Compostela/Wuhan (China). October 20 2025. The Galician biotechnology company, based in Santiago de Compostela, SunRock Biopharma, has signed a strategic alliance with the Chinese multinational Chime Biologics to accelerate the development of SRB5, an innovative therapeutic antibody intended for the treatment of inflammatory bowel disease (IBD), which includes pathologies such as Crohn’s disease or ulcerative colitis.
The agreement combines the scientific capabilities of SunRock, which researches and designs its antibodies at the Sionlla Biopole-Center for Innovative Services for Biotechnology Companies (CSIEB) in Santiago de Compostela, with the biotechnology manufacturing platform of Chime Biologics, which operates under international GMP (Good Manufacturing Practices) standards. This collaboration facilitates large-scale antibody production and accelerates the necessary preclinical and regulatory processes to bring the antibody to patients.
SRB5 is a next-generation monoclonal antibody that selectively eliminates cells responsible for chronic intestinal inflammation. It represents the latest development within SunRock Biopharma’s anti-CCR9 platform, a pioneering line of research that could also have future applications in certain types of aggressive cancers.
“This collaboration reinforces our strategy of working with top-tier partners at every stage of development,” explains Laureano Simón, CEO of SunRock Biopharma. “Chime Biologics’ technical expertise will allow us to scale up SRB5 under optimal conditions and move toward clinical validation of an antibody with a unique biological profile.”
From Chime Biologics, its president, Jimmy Wei, highlights the value of the project:
“We are delighted to collaborate with SunRock on this promising anti-CCR9 antibody. Our expertise in biotechnology manufacturing will help accelerate the development of innovative therapies for millions of patients affected by inflammatory diseases.”
A Galician company with a global reach
Founded in Santiago de Compostela, SunRock Biopharma has established itself as one of Spain’s most active biotechnology companies in the development of next-generation therapeutic antibodies for both oncology and inflammatory diseases. Its model is based on collaboration with universities and research centers in Europe, the United States, and Asia, and on technology transfer to major pharmaceutical companies once initial clinical trials are completed. The SunRock team comprises scientists and managers with extensive international experience and maintains a network of collaborators in various countries. The company combines Galician innovation with a global perspective, aiming to position Galicia on the international biotechnology map.
+ info: Bioga Press Office. 679.486.961.
SunRock Biopharma: www.sunrockbiopharma.com
SunRock Biopharma Press: media@sunrockbioparma.com
